Movano Inc. — FY2023 Form 10-K
Filing identity: The supplied filing is for Movano Inc. (Nasdaq: MOVE), not Corvex, Inc. It covers the fiscal year ended December 31, 2023; the 10-K was signed April 16, 2024.
Business context
Movano is a development-stage health technology company developing wearables and sensor technology. Its Evie Ring, a women-focused general wellness wearable, launched in November 2023. The company is also developing Evie Med, which would require FDA clearance for medical use, and a proprietary sensor intended to enable non-invasive glucose and cuffless blood-pressure monitoring.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | No revenue recognized | No revenue reported |
| Research and development expense | $16.9 million | $19.0 million |
| Sales, general and administrative expense | $12.8 million | $11.5 million |
| Total operating expenses / operating loss | $29.7 million | $30.5 million |
| Net loss | $29.3 million | $30.3 million |
| Net loss per share | $0.63 | $0.92 |
| Cash used in operating activities | $26.2 million | $24.9 million |
| Cash and cash equivalents at year-end | $6.1 million | $10.8 million |
Margins are not meaningful because the company had no recognized revenue. Although Movano reported more than $1 million in Evie Ring sales during the first ten days after launch, it said no rings had been delivered by year-end; customer prepayments resulted in $1.3 million of deferred revenue. Inventory was $1.1 million at year-end.
Total assets were $9.4 million and total liabilities $6.0 million at December 31, 2023. Current assets were $8.5 million versus current liabilities of $5.9 million. The filing does not report material conventional borrowing; disclosed lease liabilities totaled $267,000. The company said year-end cash would not fund operations for the next 12 months and disclosed substantial doubt about its ability to continue as a going concern.
Changes, outlook and notable developments
- Net loss narrowed by about $1.0 million, as lower R&D costs and higher interest income more than offset increased SG&A. Operating cash use increased by $1.3 million.
- Movano raised $21.6 million net through public offerings and ATM sales during 2023. About $44.4 million remained available under its ATM program at year-end, but the company said additional financing was necessary.
- On April 5, 2024, after year-end, the company closed a private placement generating approximately $24.1 million gross, before about $1.4 million of fees. The offering included common shares or pre-funded warrants and warrants, creating significant potential dilution.
- The company withdrew its 2023 FDA 510(k) submission for Evie Med’s pulse oximeter after FDA review and device changes. Following a second pivotal hypoxia study completed in January 2024, management planned to resubmit in April 2024 and expected a decision by July 2024; these were expectations, not achieved outcomes.
- Management cited an October 2023 blood-pressure prototype study with 44 participants and a reported mean absolute difference of 5.9 mmHg. The filing also cautions that the planned glucose and blood-pressure product has not yet demonstrated commercial-level accuracy.
- Nasdaq notified the company in November 2023 that its share price had failed the $1 minimum bid requirement. The stated initial compliance deadline was May 13, 2024; delisting remained a risk.
Risks and controls
- Early-stage business with no recognized revenue to date, recurring losses, substantial cash burn and dependence on further financing; equity financing may dilute shareholders.
- Commercial success depends heavily on the Evie Ring, while medical-device clearance, performance of developing technology, market acceptance and manufacturing or distribution arrangements remain uncertain.
- FDA and FCC requirements, competition from better-resourced companies, intellectual-property and product-liability exposure, and privacy and cybersecurity risks could delay or impair commercialization.
- Management concluded disclosure controls were ineffective and identified a material weakness in financial close and reporting controls, including account reviews and information-technology general controls. No resulting financial-statement misstatement was identified. The auditor’s opinion on the financial statements was unqualified but included a going-concern uncertainty.
- No material pending legal proceeding was reported. The filing reported no material cybersecurity incident known to the company as of its filing date.
Key facts for investors to verify
- Whether the April 2024 financing provides adequate runway, and the resulting share count and dilution after warrant exercises.
- Evie Ring units delivered, recognized revenue, returns, customer demand and inventory position after year-end.
- Current FDA submission status and any decision or additional study requirements for Evie Med; distinguish wellness-device claims from cleared medical indications.
- Progress on remediating the material weakness and restoring effective disclosure and financial-reporting controls.
- Nasdaq bid-price compliance and any subsequent listing notices or extensions.